Novel Clinical and Molecular Findings in Chinese Families with Dyschromatosis Symmetrica Hereditaria
Suju Luo,Yan Zheng,Hongbo Ni,Yan Liu,Yuanjun LIU,Xiaoli LI,Q. Liu
DOI: https://doi.org/10.1111/j.1346-8138.2011.01431.x
2011-01-01
Abstract:Dear Editor, Dyschromatosis symmetrica hereditaria (DSH, Mendelian Inheritance in Man no. 127400) is a pigmentary genodermatosis characterized by a mixture of hyperpigmented and hypopigmented macules distributed on the back of the extremities. It is caused by mutation in the double-stranded RNA-specific adenosine deaminase (DSRAD) gene, which is also called the ADAR1 gene encoding RNA-specific adenosine deaminase.1 We describe an unusual case of concomitant DSH and psoriasis and an interesting case of DSH associated with depression. We performed direct nucleotide sequencing of the DSRAD gene in three Chinese families with DSH. Our first case was a 32-year-old man with typical lesions of DSH on the back of his hands, but not on his feet. The patient reported erythematous, scaly papules and plaques appeared on his limbs and trunk 4 years previously (Fig. 1a,b). The biopsy specimen taken from the erythematous and scaly papules demonstrated parakeratosis with no granular layer, thickened epidermal papilla and dilated capillaries in the papillary dermis (Fig. 1c). These pathological findings were consistent with psoriasis. On the basis of clinical and histological findings, concomitant DSH and psoriasis were diagnosed. Our second case was a 52-year-old woman with typical lesions of DSH on the extremities. She reported that she felt isolated and worried of the lesions being seen by others because of the unpleasant appearance. When she was 18-years-old, she developed serious depression and wanted to commit suicide because of worrying that her marriage was being affected by the unpleasant appearance. (a) Hyperpigmented and hypopigmented macules on the back of the patient’s hands and erythematous, scaly papules and plaques involving his upper limbs. (b) Erythematous, scaly papules and plaques involving his lower limbs and no hyperpigmented and hypopigmented macules on the back of his feet. (c) Histological features of psoriasis: parakeratosis with no granular layer, thickened epidermal papilla and dilated capillaries in the papillary dermis (hematoxylin–eosin, original magnification ×100). We performed a study of three families with DSH, including these two families. The study was approved by the Ethics Committee of Tianjin Medical University and informed consent was obtained from all participants. Genomic DNA was extracted (Tianamp Blood DNA Kit; Tiangen, Beijing, China) from whole blood samples of the patients, healthy family members and 100 unrelated controls. All translated exons and exon–intron boundaries sequences of the DSRAD gene were amplified by polymerase chain reaction (PCR). The amplified products were purified (High Pure PCR Product Purification Kit; Roche Applied Science, Mannheim, Germany) and sequenced using dye terminator chemistry on an automated DNA sequencer. We identified three novel heterozygous mutations in the ADAR1 gene as follows: (i) 1470 T→A (Fig. 2a) causing the nonsense mutation p.C490X in exon 2 identified in the patient with concomitant DSH and psoriasis; (ii) 1156 A→G (Fig. 2b) causing the missense mutation p.N386D in exon 2 identified in the patient with DSH and associated depression; and (iii) 3483 T→A (Fig. 2c) causing missense mutation p.I1161M in exon 15. The same mutations were not found in the healthy members of the families and the 100 unrelated normal controls, suggesting that they were not the common polymorphisms. None of the mutations in our patients have been previously reported. (a) One-base substitution of 1470 T→A mutation in the patient with concomitant dyschromatosis symmetrica hereditaria (DSH) and psoriasis and the 100 unrelated normal controls in exon 2 of the ADAR1 gene. Arrow, position of mutation site. (b) One-base substitution of 1156 A→G mutation in the patient with DSH and associated depression and the 100 unrelated normal controls in exon 2 of the ADAR1 gene. Arrow, position of mutation site. (c) One-base substitution of 3843 T→A mutation in the other case of familial DSH and the 100 unrelated normal controls in exon 15 of the ADAR1 gene. Arrow, position of mutation site. The mutation p.C490X in exon 2 identified in our patient of concomitant DSH and psoriasis is different from the mutation reported by Shi et al.2 in 2011 in another patient of DSH associated with psoriasis, who was harboring TCT to A resulting in a frame-shift mutation in exon 9 in the DSRAD gene. The nonsense mutation p.C490X results in the lack of 736 amino acids leading to truncated proteins with no functional activity. Relationships between the genotype and phenotype in DSH patients associated with psoriasis cannot be found because only two mutations distributed in different exons of ADAR1 have been reported in concomitant patients. It seems that coexistence of these two unrelated disease is a simple coincidence more than an intrinsic mechanism.2 Depression is one of the most commonly diagnosed mental disorders, which is associated with many factors: social and occupational impairment, poorer quality of life, physical conditions such as cardiovascular disorders, respiratory syndromes, diabetes, HIV, irritable bowel syndrome and stroke.3 In our patient with DSH and associated depression, there was no comorbidity as described above. The coexistence of DSH and depression is uncommon. These findings indicate to a certain degree that DSH may have psychosocial impact, which differ from previous reports stating that lesions of DSH do not affect the general health of the patient besides the unpleasant appearance4,5 and also differ from another two previously reported cases of DSH associated with organic changes in the nervous system, who presented with dystonia, mental deterioration and brain calcification.6,7 The mechanism by which mutations in the ADAR1 gene cause DSH still remains unknown. Miyamura et al. speculated that when melanoblasts migrate from the neural crest to the skin during development, a greater reduction in ADAR1 activity might occur at anatomic sites distant from the neural crest. Failure of correct RNA editing may induce the differentiation of melanoblasts to hyperactive or hypoactive melanocytes, then colonizing in an irregular distribution in the skin lesions.4 In conclusion, we describe an interesting case of DSH associated with depression and an unusual case of concomitant DSH and psoriasis. We identified three novel mutations in the ADAR1 gene, which expands the spectrum of ADAR1 mutations involved in DSH. We thank all the patients for their collaboration. This work was supported by the National Natural Science Foundation of China (no. 30901297) and Ph.D. Programs Foundation of Ministry of Education of China (no. 20090201120074).